Parkinsons in the News USA.Summary
The stock already popped on FDA approval of GOCOVRI a few weeks ago.
Adamas put together an investor presentation in which they revealed their pricing and market outlook for GOCOVRI.
Adamas could go quite a bit higher, but there certainly are risks.
When the FDA approved the Adamas' (ADMS) drug, GOCOVRI, to treat dyskinesia in patients with Parkinson's Disease on Aug. 24th, the stock jumped from about $14 up to about $21. Dyskinesia is involuntary muscle movements that affects as many as 200,000 of the 1 million patients with Parkinson's Disease in the U.S. GOCOVRI is now the only FDA approved treatment for dyskinesia in patients with Parkinson's Disease.
Forum Members have already Highlighted the side effects from drug use and the numbers of up to 200,000 is tiny compared to the Patient Market of LCT.
But good on ADMS commercialisation isn't an easy task and $21 and climbing is a great result for those that invested. releasing their pricing and market outlook has detailed a clearer picture of Revenues.
Good News.
Parkinsons in the News USA.Summary The stock already popped on...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.49M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.8¢ | 0.7¢ | $5.169K | 715.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 8014267 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1382834 | 9 |
View Market Depth
| Last trade - 12.28pm 06/09/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |